MDA435/LCC6 and MDA435/LCC6MDR1: Ascites models of human breast cancer

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 154-161

  Leonessa, F ^a   Green, D ^a   Licht, T ^b   Wright, A ^a   Wingate Legette, K ^a   Lippman, J ^a   Gottesman, M M ^b   Clarke, R ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Animal models; Breast cancer; Drug screening; MDR1, P glycoprotein

Indexed keywords

AMIFOSTINE; CARMUSTINE; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; PACLITAXEL;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES CELL; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER MODEL; CELL GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; P-GLYCOPROTEIN; RATS; RATS, NUDE; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 0030050691     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.29     Document Type: Article

References (52)

1. BATIST G, TUPLE A, SINHA BK, KATKI AG, MYERS CE AND COWAN KH. (1986). Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem., 261, 15544-15549.
2. BENDER RA, HAMEL E AND HANDE KR. (1990). Plant alkaloids. In Cancer Chemotherapy: Principles and Practice. Chabner BA and Collins JM. (eds). pp. 253-275. JB Lippincott: Philadelphia.
3. BERGER DP, WINTERHALTER BR AND FIEBIG HH. (1991). Conventional chemotherapy. In The Nude Mouse in Oncology Research. Boven F. and Winograd B. (eds). pp. 165-184. CRC Press: Boca Raton.
4. BOTTI G, CHIAPPETTA G, D'AIUTO G, DE ANGELIS E, DE MATTEIS A, MONTELLA M, PICONE A AND CASCIONE F. (1993). PCNA/ cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori, 79, 214-218.
5. BOYD MR. (1989). Status of the NCI preclinical antitumor drug discovery screen. PPO Updates, 3, 1-12.
6. CAILLEAU R, YOUNG R, OLIVE M AND REEVES WJ. (1974). Breast tumor cell lines from pleural effusions. J. Natl Cancer Inst., 53, 661-674.
7. CAILLEAU R, OLIVE M AND CRUCIGER QVA. (1978). Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro, 14, 911-915.
8. CLARKE R, BRÜNNER N, THOMPSON EW, GLANZ P, KATZ D, DICKSON RB AND LIPPMAN ME. (1989). The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J. Endocrinol., 122, 331-340.
9. CLARKE R, DICKSON RB AND LIPPMAN ME. (1992a). Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit. Rev. Oncol. Hematol., 12, 1-23.
10. CLARKE R, CURRIER S, KAPLAN O, LOVELACE E, BOULAY V, GOTTESMAN MM AND DICKSON RB. (1992b). Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J. Natl Cancer Inst., 84, 1506-1512.
11. COLVIN M AND CHABNER BA. (1990). Alkylating agents. In Cancer Chemotherapy: Principles and Practice, Chabner BA and Collins JM. (eds). pp. 276-313. JB Lippincott: Philadelphia.
12. DE VITA, VT. (1989). Principles of chemotherapy. In Cancer Principles and Practice of Oncology, 3rd edn. De Vita VT, Hellman S and Rosenberg SA. (eds). pp. 276-300. JB Lippincott: Philadelphia.
13. DHAINAUT A, RÉGNIER G, ATASSI G, PIERRÉ A, LÉONCE S, KRAUS-BERTHIER L AND PROST J-F. (1992). New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem., 35, 2481-2496.
14. DONEHOWER RC AND ROWINSKY EK. (1994). Paclitaxel. PPO Updates, 8 (10), 1-16.
15. FORD JM, BRUGGEMANN EP, PASTAN I, GOTTESMAN MM AND HAIT WN. (1990). Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res., 50, 1748-1756.
16. FRACCHIA AA, KNAPPER WH, CAREY JT AND FARROW JH. (1970). Intrapleural chemotherapy for effusion from metastatic breast cancer. Cancer, 26, 626-629.
17. FRANDSEN TL, BOYSEN BE, JIRUS S, SPANG-THOMSEN M, DANO K, THOMPSON EW AND BRUNNER N. (1992). Experimental models for the study of human cancer cell invasion and metastasis. Fibrinolysis, 6, (suppl 4), 71-76.
18. GAREWAL HS. (1988). Mitomycin C in the chemotherapy of advanced breast cancer. Semin. Oncol., 15, (suppl 4), 74-79.
19. GHIORGHIS A, TALEBIAN A AND CLARKE R. (1991). In vitro antineoplastic activity of N7-substituted Mitomycin C analogues (MC-77 and MC-62) against human breast cancer cell lines. Cancer Chemother. Pharmacol., 29, 290-296.
20. GLASS AG AND HOOVER RN. (1990). Rising incidence of breast cancer: relationship to stage and receptor status. J. Natl Cancer Inst., 82, 693-696.
21. GOLDMAN CA, SKINNIDER LF AND MAKSYMIUK AW. (1993). Interferon instillation for malignant pleural effusions. Ann. Oncol., 4, 141-145.
22. GOLDSTEIN LJ, GALSKI H, FOJO A, WILLINGHAM M, LAI S, GAZDAR A, PIRKER R, GREEN A, CRIST W, BRODEUR GM, LIEBER M, COSSMAN J, GOTTESMAN M AND PASTAN I. (1989). Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst., 81, 116-124.
23. GREEN D, WRIGHT A, SCHEIN P AND CLARKE R. (1992). WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc. Am. Assoc. Cancer Res., 33, 490.
24. HENDERSON IC. (1991). Chemotherapy for metastatic disease. In Breast Diseases, Harris JR, Hellman S, Henderson IC and Kinne DW. (eds). pp. 604-665. JB Lippincott: Philadelphia.
25. HENDERSON IC AND SHAPIRO CI. (1991). Adjuvant chemotherapy: an overview. In Medical Management of Breast Cancer, Powles T and Smith IE. (eds). pp. 197-215. Dunitz: London.
26. HILL RP. (1987). Excision assays. In Rodent Tumor Models in Experimental Cancer Therapy, Kallman RF. (ed.) pp. 67-75. Pergamon Press: New York.
27. JONAT W AND MAAT H. (1978). Some comments on the necessity of receptor determinations in human breast cancer. Cancer Res., 38, 4305-4306.
28. KOH EH, CHUNG HC, LEE KB, LIM HY, KIM JH, ROH JK, MIN JS, LEE KS AND KIM BS. (1992). The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med. J., 33, 137-142.
29. LEONESSA F, BOULAY V, WRIGHT A, THOMPSON EW, BRÜNNER N AND CLARKE R. (1991). The biology of breast tumor progression: acquisition of hormone-independence and resistance to cytotoxic drugs. Acta Oncol., 31, 115-123.
30. LEONESSA F, JACOBSON M, BOYLE B, LIPPMAN J, MCGARVEY M AND CLARKE R. (1994). The effect of tamoxifen on the multidrug resistant phenotype in human breast cancer cells: isobologram, drug accumulation and gp-170 binding studies. Cancer Res., 54, 441-447.
31. MESCHTER CL, CONNOLLY JM AND ROSE DP. (1992). Influence of regional location of the inoculation site and dietary fat on the pathology of MDA-MB-435 human breast cancer cell-derived tumors growing in nude mice. Clin. Exp. Metastasis, 10, 167-173.
32. MEYERS JS, RAO BR, STEVENS SC AND WHITE WL. (1977). Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular proliferation. Cancer, 40, 2290-2298.
33. MILLER AB AND BULBROOK RD. (1986). UICC multidisciplinary project on breast cancer: the epidemiology, aetiology and prevention of breast cancer. Int. J. Cancer, 37, 173-177.
34. MOULDER JE AND ROCKWELL S. (1987). Comparison of tumor assay methods. In Rodent Tumor Models in Experimental Cancer Therapy, Kallman RF. (ed.) pp. 272-278. Pergamon Press: New York.
35. MYERS CE AND CHABNER BA. (1990). Anthracyclines. In Cancer Chemotherapy: Principles and Practice. Chabner BA and Collins JM. (eds). pp. 356-381. JB Lippincott: Philadelphia.
36. PASTAN I, GOTTESMAN MM, UEDA K, LOVELACE E, RUTHERFORD AV AND WILLINGHAM MC. (1988). A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl Acad. Sci. USA, 85, 4486-4490.
37. PRICE JE, POLYZOS A, ZHANG RD AND DANIELS LM. (1990). Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res., 50, 717-721.
38. RAMU A, GLAUBIGER D AND FUKS Z. (1984). Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res., 44, 4392-4395.
39. REED E AND KOHN KW. (1990). Platinum analogues. In Cancer Chemotherapy: Principles and Practice. Chabner BA and Collins JM. (eds). pp. 465-490. JB Lippincott: Philadelphia.
40. RYGAARD K AND SPANG-THOMSEN M. (1989). 'GROWTH' - a computer program for determination of mean growth curves and calculation of response to therapy of solid tumor xenografts. In Immune-Deficient Animals in Experimental Medicine. Wu B and Zheng J. (eds). pp. 301-360. Karger: Basle.
41. SALMON SE, GROGAN TM, MILLER T, SCHEPER R AND DALTON WS. (1989). Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J. Natl Cancer Inst., 81, 696-701.
42. SANFILIPPO O, RONCHI E, DE MARCO C, DI FRONZO G AND SILVESTRINI R. (1991). Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer, 27, 155-158.
43. SCHNEIDER J, BAK M, EFFERTH T, KAUFMANN M, MATTERN J AND VOLM M. (1989). P-glycoprotein expression in treated and untreated human breast cancer. Br. J. Cancer, 60, 815-818.
44. SHEK LL AND GODLOPHIN W. (1989). Survival with breast cancer: the importance of estrogen receptor quantity. Eur. J. Cancer Clin. Oncol., 25, 243-250.
45. SICILIANO MJ, BARKER PE AND CAILLEAU R. (1979). Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res., 39, 919-922.
46. SINGH L, WILSON AJ, BAUM M, WHIMSTER WF, BIRCH IH, JACKSON IM, LOWREY C AND PALMER MK. (1988). The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (Nolvadex) trial. Br. J. Cancer, 57, 612-614.
47. SINHA BK, MIMNAUGH EG, RAJAGOPALAN S AND MYERS CE. (1989). Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res., 49, 3844-3848.
48. TRESKES M, HOLWERDA U, KLEIN I, PINEDO HM AND VAN DER VIJGH WJ. (1991). The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem. Pharmacol., 42, 2125-2130.
49. VENERONI S, ZAFFARONI N, DAIDONE MG, BENINI E, VILLA R AND SILVESTRINI R. (1994). Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur. J. Cancer, 30A, 1002-1007.
50. VERRELLE P, MEISSONNIER F, FONCK Y, FEILLEL V, DIONET C, KWIATKOWSKI F, PLAGNE R AND CHASSAGNE J. (1991). Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl Cancer Inst., 83, 111-116.
51. VICKERS PJ, DICKSON RB, SHOEMAKER R AND COWAN KH. (1988). A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone independent tumor growth. Mol. Endocrinol., 2, 886-892.
52. ZYAD A, BERNARD J, CLARKE R, TURSZ T, BROCKHAUS M AND CHOUAIB S. (1994). Human breast cancer cross-resistance to TNF and adriamycin: relationship to MDR1, MnSOD and TNF gene expression. Cancer Res., 54, 825-831.